Skip to content
DataLookout
Menu

NCT03772899

Fecal Microbial Transplantation in Combination With Immunotherapy in Melanoma Patients (MIMic)

StatusActive, Not Recruiting
PhasePhase 1
Primary completion
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 8 with changes below, 3 re-verified with no change. See every version on ClinicalTrials.gov ↗

  1. Notable Eligibility criteria expanded, about 29 words
    • Study completion pushed from Aug 2026 to Feb 2027
    • Secondary endpoints: details revised at 2 of 7 entries
    • Publications: details revised at 1 of 1 entry
  2. Minor Study completion date: Dec 2024 to Aug 2026v10
  3. Minor Primary completion date changed from estimate of Dec 2023 to Sep 14, 2021
    • Study completion date: Dec 2023 to Dec 2024
    v9
  4. Minor Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 3 of 3 sites
    v6
  5. Minor Study sites: 1 to 3
    • Secondary endpoints: 4 to 7
    • Study arms: 0 to 1
    v5
Show 2 earlier versionsHide 2 earlier versions
  1. Notable Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 1
    • Start date changed from estimate of Apr 2019 to Mar 27, 2019
    v3
  2. Notable Start date: Dec 2018 to Apr 2019v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

To evaluate the safety of combining Fecal Microbial Transplantation (FMT) using intestinal bacteria existing in the stool of healthy donors with immunotherapy in melanoma patients.
Timeframe: 60 months

Secondary (4)

Assess Objective Response Rate
To Evaluate the effect(s) combination FMT and immunotherapy has on the gut microbiome
Evaluate the effect(s) combination FMT and immunotherapy has on changes in immune blood biomarkers
Evaluate the effect(s) combination FMT and immunotherapy has on patient's metabolomics

Arms and interventions

Study InterventionExperimental

Fecal Microbial Transplantation - all patients registered on study will receive one dose (80-100mg) of FMT. This is a single arm, unblinded study.

Drugs: Fecal Microbial Transplantation

Sites

3 sites in 1 country